The world of hair restoration keeps evolving, and every so often a genuinely new idea appears. In this article based on his educational video, Dr. John Watts — dermatologist, trichologist and hair transplant surgeon in Hyderabad who has performed over 3,000 hair transplants — explains a new clinical trial compound called PP405 that might change the game for people dealing with hair loss.
Why existing treatments leave a gap
Conventional treatments — Minoxidil, biotin, Finasteride, Dutasteride, PRP therapy, Mesotherapy and stem cell treatments — are commonly used to boost hair growth. While effective for some, they primarily produce vellus hair (baby hair) rather than the long, terminal hair patients actually want.
When these fall short, people turn to hair transplant surgery, which gives long-term, natural-looking results but comes with its own challenges: time, cost and the invasiveness of the procedure.
What is PP405?
PP405 is a topical lotion developed by Pelage, a company founded in collaboration with the University of California, Los Angeles (UCLA). Applied to the scalp, it stimulates hair follicles and promotes hair growth — positioning it as a potential alternative to hair transplant surgery.
In its Phase 1 clinical trial, conducted on 20 male subjects with androgenetic alopecia, PP405 demonstrated impressive results. Pelage researchers published their findings in Dermatology Times, showing the compound effectively stimulated hair growth in trial patients.
A key safety finding: the drug did not appear in the blood. It reached the scalp and triggered follicle activity while staying localized — targeting the area that needs growth stimulation while avoiding systemic absorption.
How does it work?
Dr. Watts explains the mechanism that makes PP405 different. Even in people with hair loss, hair follicle stem cells are still present in the scalp — just in a dormant state. The active ingredient in PP405 works by awakening these dormant stem cells, prompting them to enter the active growth phase and produce new hair.
The application schedule is also strikingly short: PP405 is applied overnight for just seven days, and trials have already demonstrated visible, terminal hair growth within this period — unlike other treatments that take weeks or months to show results.
When can patients get it?
Not yet. While Phase 1 results are promising, PP405 is not available on the market. Researchers plan Phase 2 trials involving both men and women, and the drug must pass several more phases of testing and regulatory approval — including by the U.S. FDA — before commercial use. Hair loss patients will need to wait for the full completion of these trials.
The bottom line
PP405 represents a genuinely different approach: rather than slowing hair loss or growing baby hair, it aims to wake up the dormant stem cells already in your scalp. Phase 1 results — localized action, no systemic absorption, terminal hair growth after seven nights of application — are encouraging. But it remains experimental. Until it clears further trials and FDA approval, proven treatments and a proper diagnosis remain your best path.
This article is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified dermatologist for diagnosis and treatment.
Frequently asked questions
What is PP405?
PP405 is an experimental topical lotion developed by Pelage in collaboration with UCLA. It stimulates hair growth by awakening dormant hair follicle stem cells in the scalp.
How is PP405 different from Minoxidil or Finasteride?
Conventional treatments mainly produce vellus (baby) hair. PP405 activates dormant follicle stem cells to enter the growth phase, and Phase 1 trials showed visible terminal hair growth after just seven nights of application.
Did the Phase 1 trial show PP405 is safe?
In the trial on 20 male subjects with androgenetic alopecia, the drug did not appear in the blood — it acted locally on the scalp without systemic absorption.
Can I buy PP405 now?
No. It must still go through Phase 2 trials (involving men and women) and further testing and regulatory approval, including from the US FDA, before it reaches the market.
